On March 29, 2024, Bluejay Diagnostics, Inc. provided notice to DLA, LLC that the Company has terminated the scope of work and master services agreement between the Company and DLA, effective immediately. In connection therewith, Frances Scally, who had served as the Company?s Interim Chief Financial Officer pursuant to such agreements with DLA, ceased serving as an officer of the Company. In connection with these matters, the Board of Directors of the Company (the ?Board?) has designated Neil Dey, the Company?s President and Chief Executive Officer, as the Company?s the principal financial and accounting officer, in addition to serving as principal executive officer.